The RASolute 302 trial represents a breakthrough in pancreatic cancer treatment, successfully doubling patient survival compared with standard care. In this episode of MedInsights Unleashed, Prof. Philip Philip, Professor of…
In this episode of MedInsights Unleashed, John Collins speaks with Professor Gregory Randolph MD, FACS, FACE, Bertucci Chair in Thyroid Surgical Oncology at Harvard Medical School, about the evolving role…
In this episode of MedInsights Unleashed, John Collins speaks with Devin Hinchcliffe about one of the most important life-saving interventions in medicine and emergency care — CPR. The discussion explores…
In this episode of MedInsights Unleashed, Wayne Paterson, Vice Chairman and CEO of Anteris Technologies, joins us to discuss one of the fastest evolving areas in structural heart disease —…
In this episode of MedInsights Unleashed, John Collins speaks with Patrick Coyle about the often-overlooked journey patients face after receiving a prescription. The conversation explores the complex system behind drug…
In this episode of MedInsights Unleashed, Professor Markus Peck-Radosavljević, MD, MBA—Professor of Medicine and Chairman of the Department of Internal Medicine & Gastroenterology at Klinikum Klagenfurt, Austria— discusses evolving treatment…
In this episode of MedInsights Unleashed, the discussion focuses on advanced chronic spine pain and when surgery becomes part of the care pathway. Dr. Rohan R. Lall, neurosurgeon at M…
Dr. Lori Wirth, MD—Elizabeth and Michael Ruane Chair of Endocrine Oncology; Medical Director of the Massachusetts General Hospital Center for Head and Neck Cancers; and Professor of Medicine at Harvard…
In this MedInsights Unleashed episode, we explore an emerging treatment for chronic degenerative disc disease called Hydrafil. Our guests are Bill Niland, CEO of ReGelTec Inc. and Dr. Anthony Lowman, PhD, Professor of Biomedical Engineering and Co-Founder/Chief Medical Officer at ReGelTec. They…
In this episode of MedInsights Unleashed, Professor Pierre Gholam, MD., FAASLD, AGAF, returns to explore the transformative potential of GLP1-based therapies beyond diabetes and obesity. The discussion highlights how these drugs may play a groundbreaking…